AVEO AVEO Pharmaceuticals Inc.

1.95
-0.04  -2%
Previous Close 1.99
Open 1.98
Price To Book -4.06
Market Cap 244425866
Shares 125,346,598
Volume 1,256,152
Short Ratio
Av. Daily Volume 2,862,937

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced December 7, 2017.
Ficlatuzumab and cetuximab
Head and neck squamous cell carcinoma (HNSCC)
Phase 2 data at ESMO 2018 noted 56% ORR.
Tivozanib + Opdivo
Renal cell cancer (RCC)
Announced September 12, 2016 that its Phase 2 trial has been discontinued
Ficlatuzumab
EGFR-mutated Non-small cell lung cancer (NSCLC)
Phase 3 PFS data met primary endpoint. OS data due August 2019, preliminary analysis noted no difference in OS.
TIVO-3 - tivozanib
Third line treatment of patients with renal cell cancer

Latest News

  1. 5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride
  2. AVEO Oncology Announces Immuno-Oncology Clinical Collaboration with AstraZeneca
  3. Why AVEO Pharmaceuticals Stock Tanked Last Month
  4. AVEO Oncology Announces Extension of Debt Facility Interest Only Period
  5. 2 Small Biotech Stocks That Insiders Are Buying
  6. New Research Coverage Highlights AVEO Pharmaceuticals, GMS, R1 RCM, Installed Building Products, Stoneridge, and Chicago Rivet & Machine — Consolidated Revenues, Company Growth, and Expectations for 2018
  7. Former Aveo CFO misled biotech's investors, jury finds
  8. 4 Healthcare Stocks You Should Get To Know Before 2019
  9. Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
  10. AVEO Oncology to Present at the 30th Annual Piper Jaffray Healthcare Conference
  11. AVEO Oncology Announces $2M Milestone Payment from EUSA Pharma Related to German Commercialization of FOTIVDA®
  12. Drug Sales Up, Biotech Stocks Down, Here's a Profit Opportunity
  13. AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark
  14. AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates
  15. AVEO: 3Q Earnings Snapshot
  16. AVEO Reports Third Quarter 2018 Financial Results and Provides Business Update
  17. AVEO Oncology Announces Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma Meets Primary Endpoint
  18. Analysts Estimate AVEO Pharmaceuticals (AVEO) to Report a Decline in Earnings: What to Look Out for
  19. AVEO Oncology and EUSA Pharma Announce Updated Interim Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma
  20. Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals — Discovering Underlying Factors of Influence

SEC Filings

  1. CT ORDER - Confidential treatment order 181215504
  2. CT ORDER - Confidential treatment order 181215501
  3. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181205744
  4. 8-K - Current report 181171342
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181171273
  6. 8-K - Current report 181160134
  7. 424B5 - Prospectus [Rule 424(b)(5)] 181026576
  8. 8-K - Current report 181026551
  9. 424B5 - Prospectus [Rule 424(b)(5)] 181024688
  10. 8-K - Current report 181014386